Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(5 citation statements)
references
References 16 publications
0
5
0
Order By: Relevance
“…Another broadly researched strategy for enhanced therapeutic effects in cancer therapy is using several drugs encapsulated in a nanocarrier. The combination of DOX and raloxifene properties was proposed as a suitable strategy for preparing a targeted platform for breast cancer cells [ 44 ]. Raloxifene belongs to selective estrogen receptor modulators that could inhibit human mammary tumor cells.…”
Section: Cs Np Platforms For a Specific Drug Deliverymentioning
confidence: 99%
“…Another broadly researched strategy for enhanced therapeutic effects in cancer therapy is using several drugs encapsulated in a nanocarrier. The combination of DOX and raloxifene properties was proposed as a suitable strategy for preparing a targeted platform for breast cancer cells [ 44 ]. Raloxifene belongs to selective estrogen receptor modulators that could inhibit human mammary tumor cells.…”
Section: Cs Np Platforms For a Specific Drug Deliverymentioning
confidence: 99%
“…The CS modification appears to be vital for metal‐ and carbon‐based nanocarriers, as they may show toxicity toward normal cells and such modification improves their biocompatibility (Figure 8 ). 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 …”
Section: Nanostructures Of Chitosan‐doxorubicinmentioning
confidence: 99%
“…One of the other primary concerns among those who develop nanocarriers for targeted therapy is that of side effects, which encourages one to make efforts toward developing such delivery particles using natural sources. Mohammadi et al (2020) developed chitosanraloxifene nanoparticles, which were further loaded with the anti-cancer drug Doxorubicin and exhibited more than 95% drug loading along with a commendable 60% drug release. However, the use of natural resources for the development of ER targeted therapeutics is not limited to their incorporation into delivery systems alone.…”
Section: Er-targeted Nanotherapeutics For Cancermentioning
confidence: 99%